Details of the Drug Combination

General Information of Drug Combination (ID: DCKDD7Y)

Drug Combination Name
Erythromycin Ampicillin
Indication
Disease Entry Status REF
Preterm Premature Rupture of Membranes (PPROM) Phase 3 [1]
Component Drugs Erythromycin   DM4K7GQ Ampicillin   DMHWE7P
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Erythromycin
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Acute gonococcal cervicitis N.A. Approved [2]
Acute otitis media AB00 Approved [2]
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Cholangitis N.A. Approved [2]
Gastroparesis DA41.00 Approved [2]
Hepatic coma N.A. Approved [2]
Inclusion conjunctivitis N.A. Approved [2]
Legionnaires' disease N.A. Approved [2]
Listeriosis N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Preterm premature rupture of the membranes N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Syphilis N.A. Approved [2]
Urinary tract infection GC08 Approved [2]
Erythema ME64.0 Investigative [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Erythromycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [8]
------------------------------------------------------------------------------------
Erythromycin Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [13]
------------------------------------------------------------------------------------
Erythromycin Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [15]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [18]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Metabolism [16]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Metabolism [19]
Beta-glucuronidase (uidA) DE7IQ34 A0A2A5L2J1_LACRH Metabolism [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Erythromycin Interacts with 27 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [21]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [22]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [23]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [24]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Decreases Expression [6]
Serine protease hepsin (HPN) OT7QNA61 HEPS_HUMAN Increases Expression [6]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Increases Expression [6]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [6]
Lanosterol synthase (LSS) OT9W2SFH LSS_HUMAN Increases Expression [6]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Increases Expression [6]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Increases Expression [6]
Fibronectin type III domain-containing protein 4 (FNDC4) OTOQK0WK FNDC4_HUMAN Decreases Expression [6]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [6]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Decreases Expression [25]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Increases Expression [26]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [27]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [28]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [29]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Affects Expression [29]
L-selectin (SELL) OT6RAJZR LYAM1_HUMAN Increases Expression [7]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [7]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [29]
Hematopoietic progenitor cell antigen CD34 (CD34) OT1MOFLZ CD34_HUMAN Increases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [30]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) OT8SPJNX KCNQ1_HUMAN Increases ADR [31]
Misshapen-like kinase 1 (MINK1) OTKB0RA8 MINK1_HUMAN Increases ADR [31]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases ADR [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DOT(s)
Indication(s) of Ampicillin
Disease Entry ICD 11 Status REF
Acute epiglottitis N.A. Approved [4]
Acute gonococcal cervicitis N.A. Approved [4]
Acute otitis media AB00 Approved [4]
Bacillary dysentery 1A02 Approved [4]
Bacteremia 1A73 Approved [4]
Bacterial endocarditis N.A. Approved [4]
Bacterial infection 1A00-1C4Z Approved [5]
Cholangitis N.A. Approved [4]
Chorioamnionitis N.A. Approved [4]
Dysentery N.A. Approved [4]
Escherichia coli meningitis N.A. Approved [4]
Meningococcal meningitis N.A. Approved [4]
Peritonitis N.A. Approved [4]
Pneumococcal meningitis N.A. Approved [4]
Staphylococcal pneumonia N.A. Approved [4]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Urinary tract infection GC08 Approved [4]
Paratyphoid fever N.A. Investigative [4]
Pelvic inflammatory disease GA05 Investigative [4]
Sinusitis CA0A.Z Investigative [4]
Ampicillin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [33]
------------------------------------------------------------------------------------
Ampicillin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [34]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [35]
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [36]
------------------------------------------------------------------------------------
Ampicillin Interacts with 13 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
N-acylhomoserine lactone acylase (lacA) DEIU0XN A0A0A1VBK6_9BURK Metabolism [37]
Beta-lactamase (blaB) DET9I1W BLAC_BACUN Metabolism [38]
AmpC beta-lactamase (ampC) DERI7LO A0A0H3KQ39_BURM1 Metabolism [39]
Beta-lactamase (blaB) DE3FVRW BLA2_BAC17 Metabolism [40]
Beta-lactamase (blaB) DETDS7E A0A2S0LB67_9FLAO Metabolism [40]
Beta-lactamase (blaB) DEQX0DG Q8RIK5_FUSNN Metabolism [40]
Beta-lactamase (blaB) DEC7JEF A0A1S1G219_9NEIS Metabolism [40]
Beta-lactamase (blaB) DEXB2A9 A0A379CPC3_PLESH Metabolism [41]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [42]
Beta-lactamase (blaB) DEWMGC3 A0A2U9SV73_9BURK Metabolism [40]
Beta-lactamase (blaB) DEWYT5M D4HFC4_CUTAS Metabolism [40]
Beta-lactamase (blaB) DE52KD0 Q6EZ46_RALPI Metabolism [40]
Beta-lactamase (blaB) DEG5Y4W A0A344X3A2_STASP Metabolism [40]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DME(s)
Ampicillin Interacts with 77 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Decreases Activity [43]
Phospholemman (FXYD1) OTNKT6GP PLM_HUMAN Increases Expression [32]
Interferon-related developmental regulator 1 (IFRD1) OT4SQMLQ IFRD1_HUMAN Decreases Expression [32]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [32]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [32]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Decreases Expression [32]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Decreases Expression [32]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Increases Expression [32]
Chloride intracellular channel protein 3 (CLIC3) OT5KUZ3A CLIC3_HUMAN Increases Expression [32]
Ceruloplasmin (CP) OTM8JE4Y CERU_HUMAN Increases Expression [32]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Decreases Expression [32]
Cystatin-A (CSTA) OT1K68KE CYTA_HUMAN Decreases Expression [32]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [32]
Arginase-1 (ARG1) OTHZITAM ARGI1_HUMAN Increases Expression [32]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Expression [32]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [32]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3) OT2HZK5M GTR3_HUMAN Increases Expression [32]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Increases Expression [32]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Increases Expression [32]
Transcription factor JunD (JUND) OTNKACJD JUND_HUMAN Increases Expression [32]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Increases Expression [32]
Gastricsin (PGC) OTQRITKI PEPC_HUMAN Increases Expression [32]
Parathymosin (PTMS) OT9PS4Q0 PTMS_HUMAN Increases Expression [32]
Calreticulin (CALR) OTYD2TR1 CALR_HUMAN Increases Expression [32]
Protein-lysine 6-oxidase (LOX) OT1C2HIU LYOX_HUMAN Increases Expression [32]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Increases Expression [32]
Sodium- and chloride-dependent creatine transporter 1 (SLC6A8) OT88C8JA SC6A8_HUMAN Increases Expression [32]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Decreases Expression [32]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Decreases Expression [32]
Rho GDP-dissociation inhibitor 1 (ARHGDIA) OTEXWJDO GDIR1_HUMAN Increases Expression [32]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Decreases Expression [32]
Myc-associated zinc finger protein (MAZ) OTEHKN1M MAZ_HUMAN Increases Expression [32]
Tropomyosin alpha-4 chain (TPM4) OTN4YLYR TPM4_HUMAN Increases Expression [32]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Increases Expression [32]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Decreases Expression [32]
Prostaglandin reductase 1 (PTGR1) OTMAR351 PTGR1_HUMAN Decreases Expression [32]
Ankyrin repeat domain-containing protein 1 (ANKRD1) OTHJ7JV9 ANKR1_HUMAN Increases Expression [32]
Na(+)/H(+) exchange regulatory cofactor NHE-RF2 (NHERF2) OTRHB9SR NHRF2_HUMAN Increases Expression [32]
Carbonic anhydrase 9 (CA9) OTNA51XT CAH9_HUMAN Increases Expression [32]
Dual specificity protein phosphatase 7 (DUSP7) OT6Z5AHP DUS7_HUMAN Increases Expression [32]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) OT25JBA3 F263_HUMAN Increases Expression [32]
Filamin A-interacting protein 1-like (FILIP1L) OTPY8IMS FIL1L_HUMAN Increases Expression [32]
Angiomotin (AMOT) OTWHDG9B AMOT_HUMAN Increases Expression [32]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Decreases Expression [32]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) OTDMU3GP CR3L3_HUMAN Decreases Expression [32]
Leukocyte-associated immunoglobulin-like receptor 2 (LAIR2) OTKCADXC LAIR2_HUMAN Decreases Expression [32]
Sterile alpha motif domain-containing protein 1 (SAMD1) OT2LK4JW SAMD1_HUMAN Increases Expression [32]
Lipocalin-15 (LCN15) OT9YXMIL LCN15_HUMAN Increases Expression [32]
Protein MTSS 2 (MTSS2) OTKMNSBF MTSS2_HUMAN Increases Expression [32]
Carbohydrate sulfotransferase 15 (CHST15) OTNTM2SP CHSTF_HUMAN Increases Expression [32]
Solute carrier family 22 member 15 (SLC22A15) OT60WAAI S22AF_HUMAN Decreases Expression [32]
BPI fold-containing family B member 2 (BPIFB2) OTXWTWQ9 BPIB2_HUMAN Increases Expression [32]
Arrestin domain-containing protein 4 (ARRDC4) OTINJ0FX ARRD4_HUMAN Decreases Expression [32]
Phospholipid phosphatase-related protein type 1 (PLPPR1) OT4A560N PLPR1_HUMAN Increases Expression [32]
Jun dimerization protein 2 (JDP2) OTW35WKX JDP2_HUMAN Decreases Expression [32]
Aquaporin-3 (AQP3) OT2J7JPD AQP3_HUMAN Decreases Expression [32]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Decreases Expression [32]
Small integral membrane protein 14 (SMIM14) OT47IF19 SIM14_HUMAN Decreases Expression [32]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Decreases Expression [32]
Homeobox protein Hox-D1 (HOXD1) OTN4V9ZF HXD1_HUMAN Increases Expression [32]
Regulator of cell cycle RGCC (RGCC) OTYJMLWM RGCC_HUMAN Increases Expression [32]
Serine/threonine-protein kinase Sgk2 (SGK2) OTCTVSHF SGK2_HUMAN Decreases Expression [32]
Endothelial cell-specific molecule 1 (ESM1) OT331Y8V ESM1_HUMAN Decreases Expression [32]
]-phosphatase 2, mitochondrial (PDP2) OTADNMGK PDP2_HUMAN Increases Expression [32]
Cell cycle progression protein 1 (CCPG1) OT0IHDKL CCPG1_HUMAN Decreases Expression [32]
Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) (SLC6A14) OTN51IPT S6A14_HUMAN Increases Expression [32]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [32]
Proliferation-associated protein 2G4 (PA2G4) OT7IG7HT PA2G4_HUMAN Increases Expression [32]
Pirin (PIR) OT8ALXHU PIR_HUMAN Increases Expression [44]
Tripartite motif-containing protein 16 (TRIM16) OTLRXYOZ TRI16_HUMAN Increases Expression [44]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [44]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Expression [44]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [45]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [45]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Increases Expression [45]
Excitatory amino acid transporter 2 (SLC1A2) OTEP3QGN EAA2_HUMAN Increases Expression [46]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Increases Transport [47]
------------------------------------------------------------------------------------
⏷ Show the Full List of 77 DOT(s)

References

1 ClinicalTrials.gov (NCT03060473) Treatment of ppROM With Erythromycin vs. Azithromycin Trial
2 Erythromycin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
4 Ampicillin FDA Label
5 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936.
6 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
7 The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006 Jan 20;218(1):30-8. doi: 10.1016/j.tox.2005.09.014. Epub 2005 Nov 16.
8 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
9 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
10 Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
11 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
12 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
13 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
14 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
15 Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
16 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
17 Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
18 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
19 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
20 Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
21 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
22 Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21.
23 Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother. 2004 Feb;53(2):174-9. doi: 10.1093/jac/dkh056. Epub 2004 Jan 16.
24 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
25 In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
26 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
27 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
28 Liver toxicity of macrolide antibiotics in zebrafish. Toxicology. 2020 Aug;441:152501. doi: 10.1016/j.tox.2020.152501. Epub 2020 May 23.
29 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
30 Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics. Toxicol In Vitro. 2019 Aug;58:51-59. doi: 10.1016/j.tiv.2019.03.015. Epub 2019 Mar 12.
31 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
32 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
33 Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
34 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
35 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
36 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
37 A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
38 Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
39 Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
40 Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
41 Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
42 Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
43 Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull. 2006 Aug;29(8):1559-63.
44 Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
45 Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
46 Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem. 2007 Jan 19;282(3):1727-37. doi: 10.1074/jbc.M609822200. Epub 2006 Nov 30.
47 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.